MUC17

Summary

MUC17 (mucin 17, cell surface associated, HGNC:16800) is a protein-coding gene on chromosome 7q22.1, encoding Mucin-17 (Q685J3). Probably plays a role in maintaining homeostasis on mucosal surfaces.

The protein encoded by this gene is a membrane-bound mucin that provides protection to gut epithelial cells. The encoded protein contains about 60 tandem repeats, with each repeat being around 60 aa. N-glycosylation enables the encoded protein to localize on the cell surface, while the C-terminus interacts with the scaffold protein PDZ domain containing 1 (PDZK1). Two transcript variants, one protein-coding and the other non-protein coding, have been found for this gene.

Source: NCBI Gene 140453 — RefSeq curated summary.

At a glance

• GWAS associations: 3
• Clinical variants (ClinVar): 1,013 total
• MANE Select transcript: NM_001040105

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:16800
Approved symbol	MUC17
Name	mucin 17, cell surface associated
Location	7q22.1
Locus type	gene with protein product
Status	Approved
Ensembl gene	ENSG00000169876
Ensembl biotype	protein_coding
OMIM	608424
Entrez	140453

Gene structure

Transcript identifiers

Ensembl transcripts: 4 — 2 retained_intron, 1 protein_coding, 1 nonsense_mediated_decay

ENST00000306151, ENST00000379439, ENST00000470303, ENST00000497859

RefSeq mRNA: 1 — MANE Select: NM_001040105 NM_001040105

CCDS: CCDS34711

Canonical transcript exons

ENST00000306151 — 13 exons

Exon	Start	End
ENSE00001125943	101050484	101050635
ENSE00001125949	101049324	101049382
ENSE00001125956	101048845	101048972
ENSE00001125973	101047984	101048115
ENSE00001125983	101031601	101043819
ENSE00001481048	101031120	101031221
ENSE00003490251	101051803	101051962
ENSE00003501652	101051613	101051681
ENSE00003538717	101052986	101053147
ENSE00003600143	101053339	101053436
ENSE00003646678	101056194	101056270
ENSE00003675564	101058003	101058859
ENSE00003889129	101020081	101020217

Expression profiles

Bgee: expression breadth broad, 90 present calls, max score 89.92.

FANTOM5 (CAGE): breadth tissue_specific, TPM avg 0.8090 / max 596.8564, expressed in 17 samples.

FANTOM5 promoters (5 alternative TSS)

Promoter ID	TPM avg	Samples expressed
80100	0.7426	15
80102	0.0215	9
80103	0.0181	6
80104	0.0147	5
80101	0.0121	7

Top tissues by expression

120 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
duodenum	UBERON:0002114	89.92	gold quality
small intestine Peyer’s patch	UBERON:0003454	87.00	gold quality
small intestine	UBERON:0002108	86.50	gold quality
rectum	UBERON:0001052	78.98	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	78.29	gold quality
intestine	UBERON:0000160	64.04	gold quality
transverse colon	UBERON:0001157	62.70	gold quality
colonic epithelium	UBERON:0000397	55.44	silver quality
colon	UBERON:0001155	55.06	gold quality
right lobe of liver	UBERON:0001114	50.46	gold quality
smooth muscle tissue	UBERON:0001135	50.17	gold quality
vermiform appendix	UBERON:0001154	49.98	gold quality
sural nerve	UBERON:0015488	48.74	silver quality
islet of Langerhans	UBERON:0000006	47.31	gold quality
right lung	UBERON:0002167	44.49	gold quality
mucosa of transverse colon	UBERON:0004991	43.64	silver quality
liver	UBERON:0002107	43.60	gold quality
granulocyte	CL:0000094	43.31	silver quality
prostate gland	UBERON:0002367	43.22	gold quality
muscle tissue	UBERON:0002385	43.04	gold quality
mucosa of stomach	UBERON:0001199	42.28	silver quality
muscle layer of sigmoid colon	UBERON:0035805	41.83	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	41.72	gold quality
bone marrow cell	CL:0002092	41.61	gold quality
monocyte	CL:0000576	40.94	gold quality
leukocyte	CL:0000738	40.53	gold quality
pancreas	UBERON:0001264	39.48	gold quality
skeletal muscle tissue	UBERON:0001134	38.79	gold quality
stromal cell of endometrium	CL:0002255	38.52	gold quality
hindlimb stylopod muscle	UBERON:0004252	38.41	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	15.38

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): CDX2, GATA5, NFKB1, RELA

miRNA regulators (miRDB)

58 targeting MUC17, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-4795-3P	100.00	74.62	4024
HSA-MIR-656-3P	100.00	72.15	2788
HSA-MIR-190A-3P	100.00	80.35	5520
HSA-MIR-5692B	100.00	71.32	2622
HSA-MIR-5692C	100.00	71.32	2622
HSA-MIR-1277-5P	100.00	73.95	5056
HSA-MIR-5011-5P	100.00	83.46	5820
HSA-MIR-4482-3P	99.98	72.50	3147
HSA-MIR-3148	99.97	75.06	6478
HSA-MIR-651-3P	99.94	73.48	5177
HSA-MIR-335-3P	99.93	73.36	4958
HSA-MIR-374A-5P	99.90	71.34	2923
HSA-MIR-374B-5P	99.90	69.98	2734
HSA-MIR-106A-5P	99.90	73.94	2683
HSA-MIR-17-5P	99.89	73.83	2665
HSA-MIR-106B-5P	99.88	74.72	2795
HSA-MIR-20A-5P	99.88	74.76	2769
HSA-MIR-20B-5P	99.88	74.01	2621
HSA-MIR-519D-3P	99.88	73.97	2607
HSA-MIR-526B-3P	99.88	74.06	2587
HSA-MIR-93-5P	99.88	73.98	2606
HSA-MIR-4779	99.86	66.50	1583
HSA-MIR-548AG	99.77	69.25	1492
HSA-MIR-4699-3P	99.71	70.15	3142
HSA-MIR-7154-5P	99.69	70.52	1900
HSA-MIR-548AI	99.69	69.24	1494
HSA-MIR-548BA	99.69	69.14	1514
HSA-MIR-570-5P	99.69	69.24	1494
HSA-MIR-7152-5P	99.60	69.33	2094
HSA-MIR-190A-5P	99.54	71.45	933

Literature-anchored findings (GeneRIF, showing 17)

• sequence homology & chromosome mapping (PMID:11855812)
• surface localization of the smaller subunit of MUC17 is dependent on its N-glycosylation status (PMID:12888891)
• The MUC17 sequence has been extended toward its 5’-extremity to complete the sequence and localize the promoter and regulatory elements. (PMID:16737958)
• Pdzk1 plays a specific role in stabilizing Muc17 in the apical membrane of small intestinal enterocytes. (PMID:17990980)
• Reflux laryngitis is associated with down-regulation of mucin gene expression. (PMID:18834073)
• The authors demonstrate that apically atypical enteropathogenic Escherichia coli infection is followed by increased production of secreted MUC2 and MUC5AC mucins and membrane-bound MUC3 and MUC4 mucins. (PMID:20065027)
• augments intestinal cell restitution and enhances healing of experimental colitis in mice (PMID:20211273)
• Results indicate that the potential protective effects of this membrane-bound mucin are primarily or secondarily diminished in inflammatory and neoplastic conditions. (PMID:20702471)
• Hypomethylation status in the MUC17 promoter could be a novel epigenetic marker for the diagnosis of Pancreatic ductal adenocarcinomas. (PMID:20926598)
• Both native and exogenous MUC17 play a role in attachment and invasion of enteroinvasive E. coli in colonic cell lines and in maintaining epithelial barrier function. (PMID:21393431)
• The HIF1alpha-mediated hypoxic signal pathway contributes to MUC17 expression, and DNA methylation of hypoxia responsive element could be a determinant of the hypoxic inducibility of MUC17 in pancreatic cancer cells. (PMID:22970168)
• Carbachol stimulated enterocyte MUC17 endocytosis is concomitant with NHE3 internalization and CFTR membrane recruitment. (PMID:23784542)
• MUC17 polymorphisms are involved in endometriosis development and the associated infertility in the Taiwanese population. (PMID:26285705)
• MUC17 inactivated NFkappaB to inhibit gastric cancer cell proliferation in response to pro-inflammatory cytokines. The MUC17 function was dependent on its conserved epidermal growth factor domain and on downstream sequences to enable its interaction with myosin-9, resulting in a regulatory feedback loop between myosin-9, p53, and RhoA, and then activation of p38 to negatively regulate the NFkappaB pathway in gastric ca… (PMID:31262330)
• Overexpression and increased presentation at the plasma membrane of wild-type MUC17 and its phosphodeficient variant MUC17 S-4492A protected Caco-2 cells against adhesion of enteropathogenic Escherichia coli, indicating that C-terminal phosphorylation of MUC17 may play a functional role in epithelial cell protection. (PMID:31387973)
• Acquired resistance to EGFR-TKIs in NSCLC mediates epigenetic downregulation of MUC17 by facilitating NF-kappaB activity via UHRF1/DNMT1 complex. (PMID:36778111)
• MUC17 mutations and methylation are associated with poor prognosis in adult-type diffuse glioma patients. (PMID:37562166)

Cross-species orthologs

1 orthologs

Organism	Symbol	Gene ID
mus_musculus	Muc17	ENSMUSG00000037390

Paralogs (2): MUC3A (ENSG00000169894), MUC13 (ENSG00000173702)

Protein

Protein identifiers

Mucin-17 — Q685J3 (reviewed: Q685J3)

Alternative names: Small intestinal mucin-3

All UniProt accessions (2): Q685J3, E7EPM4

UniProt curated annotations — full annotation on UniProt →

Function. Probably plays a role in maintaining homeostasis on mucosal surfaces.

Subunit / interactions. Interacts via its C-terminus with PDZK1 and this interaction appears important for proper localization.

Subcellular location. Cell membrane Secreted. Cell membrane.

Tissue specificity. Expressed almost exclusively in the intestine. Expression is especially high in both the duodenum and transverse colon. Expressed in mature absorptive cells of the small intestinal villi. No expression is detected in goblet cells. Highly expressed in pancreatic adenocarcinoma tissue (at protein level). Expression is not detectable in normal pancreas, in pancreatitis or in cell lines derived from other cancers.

Post-translational modifications. Probably cleaved within the SEA domain. N-glycosylated. Contains high mannose and complex-type glycans. The forms containing the complex type glycans localize to the cell surface. Not O-glycosylated.

Isoforms (2)

UniProt ID	Names	Canonical?
Q685J3-1	1, Major, Mb-MUC17	yes
Q685J3-2	2, Minor, s-MUC17

RefSeq proteins (1): NP_001035194* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR000082	SEA_dom	Domain
IPR000742	EGF	Domain
IPR036364	SEA_dom_sf	Homologous_superfamily
IPR053311	Mucosal_Integrity_Assoc	Family

Pfam: PF01390

UniProt features (256 total): compositionally biased region 115, repeat 59, region of interest 31, sequence variant 20, glycosylation site 13, sequence conflict 5, disulfide bond 3, topological domain 2, splice variant 2, domain 2, signal peptide 1, chain 1, site 1, transmembrane region 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

No AlphaFold model available for Q685J3 — AlphaFold DB does not currently provide models for proteins above ~3000 aa.

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Catalytic / active sites (1): 4243–4244 (cleavage)

Disulfide bonds (3): 4135–4147, 4140–4158, 4160–4169

Glycosylation sites (13): 471, 696, 898, 1345, 2077, 2194, 3344, 4116, 4205, 4236, 4267, 4297, 4305

Function

Pathways and Gene Ontology

Reactome pathways

16 pathways

ID	Pathway
R-HSA-5083625	Defective GALNT3 causes HFTC
R-HSA-5083632	Defective C1GALT1C1 causes TNPS
R-HSA-5083636	Defective GALNT12 causes CRCS1
R-HSA-5621480	Dectin-2 family
R-HSA-913709	O-linked glycosylation of mucins
R-HSA-977068	Termination of O-glycan biosynthesis
R-HSA-1643685	Disease
R-HSA-168249	Innate Immune System
R-HSA-168256	Immune System
R-HSA-3781865	Diseases of glycosylation
R-HSA-3906995	Diseases associated with O-glycosylation of proteins
R-HSA-392499	Metabolism of proteins
R-HSA-5173105	O-linked glycosylation
R-HSA-5621481	C-type lectin receptors (CLRs)
R-HSA-5668914	Diseases of metabolism
R-HSA-597592	Post-translational protein modification

MSigDB gene sets: 50 (showing top): REACTOME_INNATE_IMMUNE_SYSTEM, GOCC_CELL_SURFACE, GOMF_EXTRACELLULAR_MATRIX_STRUCTURAL_CONSTITUENT, GOCC_APICAL_PLASMA_MEMBRANE, ACEVEDO_METHYLATED_IN_LIVER_CANCER_DN, GOCC_APICAL_PART_OF_CELL, GOBP_HOMEOSTATIC_PROCESS, GOCC_SIDE_OF_MEMBRANE, GOCC_PLASMA_MEMBRANE_REGION, GOCC_GOLGI_LUMEN, WUNDER_INFLAMMATORY_RESPONSE_AND_CHOLESTEROL_UP, GOMF_STRUCTURAL_MOLECULE_ACTIVITY, REACTOME_POST_TRANSLATIONAL_PROTEIN_MODIFICATION, GOCC_EXTERNAL_SIDE_OF_PLASMA_MEMBRANE, BYSTRYKH_HEMATOPOIESIS_STEM_CELL_QTL_TRANS

GO Biological Process (1): cellular homeostasis (GO:0019725)

GO Molecular Function (3): PDZ domain binding (GO:0030165), extracellular matrix constituent, lubricant activity (GO:0030197), protein binding (GO:0005515)

GO Cellular Component (8): extracellular region (GO:0005576), Golgi lumen (GO:0005796), plasma membrane (GO:0005886), external side of plasma membrane (GO:0009897), apical plasma membrane (GO:0016324), extracellular matrix (GO:0031012), membrane (GO:0016020), cell periphery (GO:0071944)

Reactome top-level categories

Rollup of top-11 pathways:

Category	Pathways
Diseases associated with O-glycosylation of proteins	3
C-type lectin receptors (CLRs)	1
O-linked glycosylation	1
O-linked glycosylation of mucins	1
Immune System	1
Diseases of metabolism	1
Diseases of glycosylation	1
Post-translational protein modification	1
Innate Immune System	1
Disease	1
Metabolism of proteins	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	3
homeostatic process	1
protein domain specific binding	1
extracellular matrix structural constituent	1
binding	1
Golgi apparatus	1
intracellular organelle lumen	1
membrane	1
cell periphery	1
plasma membrane	1
cell surface	1
side of membrane	1
apical part of cell	1
plasma membrane region	1
external encapsulating structure	1

Protein interactions and networks

STRING

1287 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
MUC17	MUC13	Q9H3R2	934
MUC17	MUC2	Q02817	884
MUC17	MUC15	Q8N387	870
MUC17	MUC20	Q8N307	865
MUC17	MUC16	Q8WXI7	854
MUC17	MUC12	Q9UKN1	849
MUC17	MUC5B	Q9HC84	833
MUC17	MUC5AC	P98088	830
MUC17	MUC6	Q6W4X9	788
MUC17	MUC1	P13931	783
MUC17	MUC7	Q8TAX7	773
MUC17	MUC19	Q7Z5P9	727
MUC17	MUC21	Q5SSG8	720
MUC17	MUC4	Q99102	627
MUC17	PDZK1	Q5T2W1	611

IntAct

0 interactions, top by confidence:

BioGRID (4): MUC17 (Affinity Capture-MS), MUC17 (Affinity Capture-MS), MUC17 (Cross-Linking-MS (XL-MS)), NCL (Cross-Linking-MS (XL-MS))

ESM2 similar proteins: A0A0U1RQI7, A0A494C071, A6QL64, A6ZXT5, A7XUY5, E2RYF6, E2RYF7, O60732, O88799, P06916, P12021, P18583, P41809, P43537, P47179, P53353, Q00130, Q02496, Q02505, Q04893, Q05049, Q12459, Q14242, Q32KG4, Q4ZJY7, Q4ZJZ0, Q54QZ8, Q5H9R4, Q5H9T9, Q5JPF3, Q5SSG8, Q5XHX6, Q60528, Q63661, Q685J3, Q6P902, Q86VQ3, Q8JZM8, Q8N307, Q8NET4

Diamond homologs: Q685J3, Q9UKN1

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

1013 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	913
Likely benign	78
Benign	1

Top pathogenic / likely-pathogenic (0)

SpliceAI

1924 predictions. Top by Δscore:

Variant	Effect	Δscore
7:101020216:GG:G	donor_gain	1.0000
7:101020217:GG:G	donor_gain	1.0000
7:101031118:A:AG	acceptor_gain	1.0000
7:101031119:G:GC	acceptor_gain	1.0000
7:101031119:GAC:G	acceptor_gain	1.0000
7:101047982:A:AG	acceptor_gain	1.0000
7:101047983:G:GG	acceptor_gain	1.0000
7:101048112:ATAGG:A	donor_loss	1.0000
7:101048114:AGG:A	donor_loss	1.0000
7:101048115:GGTG:G	donor_loss	1.0000
7:101048116:G:GG	donor_gain	1.0000
7:101048116:GTGA:G	donor_loss	1.0000
7:101048117:T:G	donor_loss	1.0000
7:101049382:GGTA:G	donor_loss	1.0000
7:101049383:G:C	donor_loss	1.0000
7:101049383:G:GG	donor_gain	1.0000
7:101049384:T:A	donor_loss	1.0000
7:101050482:A:AG	acceptor_gain	1.0000
7:101050483:G:GC	acceptor_gain	1.0000
7:101050569:G:GT	donor_gain	1.0000
7:101050596:G:GG	donor_gain	1.0000
7:101051608:CACA:C	acceptor_loss	1.0000
7:101051610:C:G	acceptor_gain	1.0000
7:101051610:CA:C	acceptor_loss	1.0000
7:101051611:A:AG	acceptor_gain	1.0000
7:101051611:AGAC:A	acceptor_loss	1.0000
7:101051612:G:GA	acceptor_gain	1.0000
7:101051612:GA:G	acceptor_gain	1.0000
7:101051612:GAC:G	acceptor_gain	1.0000
7:101051612:GACA:G	acceptor_gain	1.0000

AlphaMissense

28727 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
7:101048962:T:G	F4218C	0.997
7:101051808:T:A	C4317S	0.997
7:101051809:G:C	C4317S	0.997
7:101048878:T:C	L4190P	0.996
7:101048904:T:C	F4199L	0.996
7:101048906:C:A	F4199L	0.996
7:101048906:C:G	F4199L	0.996
7:101048950:T:G	F4214C	0.996
7:101048961:T:C	F4218L	0.996
7:101048962:T:C	F4218S	0.996
7:101048963:C:A	F4218L	0.996
7:101048963:C:G	F4218L	0.996
7:101051809:G:A	C4317Y	0.996
7:101051810:C:G	C4317W	0.996
7:101051874:T:A	C4339S	0.996
7:101051875:G:C	C4339S	0.996
7:101048950:T:C	F4214S	0.995
7:101050519:T:C	L4253P	0.995
7:101051621:T:A	C4295S	0.995
7:101051622:G:C	C4295S	0.995
7:101051625:T:G	F4296C	0.995
7:101051808:T:C	C4317R	0.995
7:101051931:T:A	C4358S	0.995
7:101051932:G:C	C4358S	0.995
7:101048917:T:C	L4203P	0.994
7:101050513:T:A	V4251D	0.994
7:101051874:T:C	C4339R	0.994
7:101051916:T:A	C4353S	0.994
7:101051917:G:C	C4353S	0.994
7:101048085:T:A	C4169S	0.993

dbSNP variants (sampled 300 via entrez): RS1000004435 (7:101039451 G>A,T), RS1000056282 (7:101018863 G>GGCACCCCT), RS1000107887 (7:101050287 G>A,C,T), RS1000140890 (7:101041536 T>G), RS1000143207 (7:101045471 G>A), RS1000175993 (7:101028879 C>A,G,T), RS1000380907 (7:101053986 G>A), RS1000464303 (7:101029894 C>T), RS1000672526 (7:101037237 T>C,G), RS1000786179 (7:101058683 C>G), RS1000796977 (7:101028991 C>T), RS1000849679 (7:101057848 C>T), RS1000907693 (7:101057511 G>A), RS1001077508 (7:101023704 C>A,T), RS1001137305 (7:101024720 T>C)

Disease associations

OMIM: gene MIM:608424 | disease phenotypes:

GenCC curated gene-disease

Mondo (1): prostate cancer (MONDO:0008315)

Orphanet (1): Familial prostate cancer (Orphanet:1331)

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

3 associations (top):

Study	Trait	p-value
GCST007250_7	Nonunion in individuals with fractures	3.000000e-07
GCST010241_382	Apolipoprotein A1 levels	6.000000e-10
GCST010478_3	Chronic kidney disease	2.000000e-08

EFO canonical traits (2, from GWAS)

EFO ID	Trait name
EFO:0009707	fractures, ununited
EFO:0004614	apolipoprotein A 1 measurement

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D011471	Prostatic Neoplasms	C04.588.945.440.770; C12.100.500.260.750; C12.100.500.565.625; C12.200.294.260.750; C12.200.294.565.625; C12.200.758.409.750; C12.900.619.750

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

4 total (human), top 4 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Benzo(a)pyrene	affects methylation, increases mutagenesis	2
Estradiol	increases expression	1
Valproic Acid	increases methylation	1
Aflatoxin B1	decreases methylation	1

Clinical trials (associated diseases)

300 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00029224	PHASE4	COMPLETED	Treatment With Zoledronic Acid in Patients With Breast Cancer, Multiple Myeloma, and Prostate Cancer With Cancer Related Bone Lesions
NCT00035997	PHASE4	COMPLETED	Open-label Trial on the Effect of I.V. Zoledronic Acid 4 mg on Bone Density in Hormone Sensitive Prostate Cancer Patients With Bone Metastasis
NCT00063609	PHASE4	COMPLETED	The Effect of Zoledronic Acid on Bone Loss in Prostate Cancer Patients Undergoing Androgen Deprivation Therapy
NCT00103623	PHASE4	SUSPENDED	The Plenaxis® Experience Study
NCT00106392	PHASE4	COMPLETED	A Safety and Efficacy Study of Prograf in the Prevention of Erectile Dysfunction After Radical Prostatectomy
NCT00185029	PHASE4	UNKNOWN	MR-Lymphography and Lymph Node Staging in Prostate Cancer
NCT00199485	PHASE4	COMPLETED	Angelica Sinensis for the Treatment of Hot Flashes in Men Undergoing LHRH Therapy for Prostate Cancer
NCT00219219	PHASE4	COMPLETED	Zoledronic Acid in the Prevention of Skeletal-related Events in Hormone Refractory and Hormone-sensitive Prostate Cancer Patients With Bone Metastases
NCT00219271	PHASE4	COMPLETED	Effect Of Zoledronic Acid On Circulating And Bone Marrow-Residing Prostate Cancer Cells In Patients With Clinically Localized Prostate Cancer
NCT00237146	PHASE4	COMPLETED	Study to Evaluate Zoledronic Acid on Quality of Life and Skeletal-related Events as Adjuvant Treatment in Patients With Hormone-naïve Prostate Cancer and Bone Metastasis Who Have Undergone Orchiectomy
NCT00242554	PHASE4	COMPLETED	Open-label Phase IV Clinical Trial to Evaluate the Safety and Tolerability of Zoledronic Acid in Patients With Prostate Cancer and Bone Metastases
NCT00280098	PHASE4	COMPLETED	Docetaxel in the Treatment of Hormone Refractory Prostate Cancer
NCT00293696	PHASE4	COMPLETED	Casodex/Zoladex Biomarkers in Localised Prostate Cancer
NCT00334139	PHASE4	COMPLETED	Effect of Zoledronic Acid on Bone Metabolism in Patients With Bone Metastasis and Prostate or Breast Cancer
NCT00375765	PHASE4	COMPLETED	Effects On Dihydrotestosterone Regulated Gene Expression In Benign Prostatic Hyperplasia Or Prostate Cancer
NCT00391690	PHASE4	COMPLETED	Evaluation of Bone Markers as Diagnostic Tools for Early Detection of Bone Metastases in Patients With High Risk Prostate Cancer
NCT00422708	PHASE4	COMPLETED	Local Anesthesia for Prostate Biopsy
NCT00526331	PHASE4	COMPLETED	Evaluation of Arterial Pressure Based Cardiac Output for Goal-Directed Perioperative Therapy
NCT00590213	PHASE4	COMPLETED	Compare the Value of Prophylactic Versus Therapeutic Breast Radiotherapy in CASODEX
NCT00629330	PHASE4	TERMINATED	Dissemination of Prostate Cancer Screening to PCP’s in African American Communities
NCT00771966	PHASE4	COMPLETED	Radical Prostatectomy and Perioperative Fluid Therapy
NCT00805701	PHASE4	COMPLETED	Study Assessing The Efficacy And Safety Of Avodart (Dutasteride) At Improving Urinary Symptoms In Men With Prostate Cancer Who Are Undergoing Seed Implantation
NCT00859027	PHASE4	COMPLETED	Effect Of Risedronate On Bone Mass In Older Men Receiving Neoadjuvant Therapy For Prostate Cancer
NCT00906269	PHASE4	UNKNOWN	Can Hyperbaric Oxygen Improve Erectile Function Following Surgery for Prostate Cancer
NCT00953277	PHASE4	COMPLETED	Study of Nerve Reconstruction Using AVANCE in Subjects Who Undergo Robotic Assisted Prostatectomy for Treatment of Prostate Cancer
NCT00982800	PHASE4	COMPLETED	Does Postoperative Gabapentin Reduce Pain, Opioid Consumption and Anxiety and Have a Positive Effect on Health Related Quality of Life After Radical Prostatectomy?
NCT01083199	PHASE4	COMPLETED	Global Performance Evaluation of the AMS CONTINUUM™ Device
NCT01136226	PHASE4	COMPLETED	Evaluate Recovery of Testosterone for Patients Using Eligard
NCT01161563	PHASE4	COMPLETED	Randomized Crossover Trial to Assess the Tolerability of Gonadotropin Releasing Hormone (GnRH) Analogue Administration
NCT01230905	PHASE4	COMPLETED	Study to Monitor the Effects of Androgen Suppression Treatment on the Heart
NCT01296672	PHASE4	COMPLETED	3 Month Finasteride Challenge Test Can Significantly Improve the Performance of Screening for Prostate Cancer
NCT01365143	PHASE4	TERMINATED	Prospective Randomized Trial Comparing Robotic Versus Open Radical Prostatectomy
NCT01379742	PHASE4	UNKNOWN	Comparison of Between ThinSeed™ and OncoSeed™ for Permanent Prostate Brachytherapy
NCT01486563	PHASE4	COMPLETED	Hydroxyethyl Starch and Renal Function After Radical Prostatectomy
NCT01511874	PHASE4	COMPLETED	Efficacy and Safety Study of ELIGARD 22.5mg With Prostate Cancer
NCT01512472	PHASE4	TERMINATED	Firmagon (Degarelix) Intermittent Therapy
NCT01547416	PHASE4	COMPLETED	The Effect of Combined General/Epidural Anesthesia Versus General Anesthesia on Diaphragmatic Function
NCT01571544	PHASE4	COMPLETED	The Use of Thermal Suits as Preventing Hypothermia During Surgery
NCT01581749	PHASE4	UNKNOWN	Evaluation of Truebeam for Low-Intermediate Risk Prostate Cancer
NCT01649635	PHASE4	COMPLETED	Study of Cabazitaxel Combined With Prednisone and Prophylaxis of Neutropenia Complications in the Treatment of Patients With Metastatic Castration-resistant Prostate Cancer